Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)

Inclusion Criteria: * Be at least 18 years old, male or female * Have stable coronary artery disease (i.e. no acute event like myocardial infarction or PTCA less then 3 months ago) * LDL \> 100 mg/dl * HDL \< 50 mg/dl * Triglycerides \< 400 mg/dl * No Nicotine abuse for at least 3 months * Statin-therapy for more than 4 weeks * Give a written informed consent * Have the ability to understand the requirements of the study, and agree and be able to return for the required assessments. Exclusion Criteria: * Women of childbearing potential, pregnancy or being lactating * Current participation in another clinical trial * Have other severe concurrent illness (e.g., active infection, malignancy) * Have a history of alcohol or drug abuse within 3 months of admission or factors making follow-up difficult or unlikely. * Have significant or unexplained liver dysfunction or chronic increased levels of transaminases (ALT, AST) * Suffer from myopathy, active peptic disease or arterial bleeding * Have a known hypersensitivity against niacin or statins * Are actually treated with any of itraconazole, ketoconazole, HIV-Protease-Inhibitors, erythromycin, clarithromycin, telithromycin, nefazodone. * Actual therapy with ezetimibe * Diabetes mellitus Type I